MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors

Acta Biochim Biophys Sin (Shanghai). 2014 Jan;46(1):72-5. doi: 10.1093/abbs/gmt118. Epub 2013 Nov 10.


Gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. Though imatinib improves the outcome, drug resistance remains the major problem for extending patient survival. Genetic mutation of the drug targets is the known mechanism for imatinib resistance. However, it cannot explain all of the phenomena of imatinib resistance, and numerous additional mechanisms have been proposed to account for imatinib resistance in various model systems. In this study, we applied the SYBR-green quantitative polymerase chain reaction-based array approach to screen the differentially expressed miRNAs between primary GIST patients and imatinib-resistant patients. The selected candidate miRNAs were validated in a cohort of 12 GIST patients. We found that low expression of miR-320a was correlated with short time to imatinib resistance, and proposed the potential mechanism of miR-320a for imatinib resistance.

Keywords: gastrointestinal stromal tumor; imatinib resistant; miR-320a.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Down-Regulation
  • Drug Resistance, Neoplasm / genetics*
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / genetics*
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / genetics*
  • Gastrointestinal Stromal Tumors / pathology
  • Humans
  • Imatinib Mesylate
  • MicroRNAs / genetics*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*


  • Antineoplastic Agents
  • Benzamides
  • MIRN320 microRNA, human
  • MicroRNAs
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate